Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
Tommy Thompson submitted a Rule 144 notice regarding 2,000 shares of Common Stock of the issuer. The filing lists the planned transfer as a Stock Option Exercise on 03/26/2026 for cash. The notice also records a prior sale of 2,000 shares on 03/04/2026 for $978,839.40.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised 9,500 stock options at $146.03 per share and acquired 9,500 shares of common stock on March 24, 2026. She then sold 9,500 common shares in multiple open‑market trades at prices between approximately $516.84 and $536.02, leaving 40,513 shares held directly.
The filing also lists additional indirect holdings, including shares held by her spouse and in various family trusts. A footnote states these transactions were made under a pre‑arranged 10b5‑1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $135.42 per share and, on the same date, sold 10,000 shares in multiple open-market trades at reported prices such as $518.2830, $529.0430 and $536.2750 per share. Following these transactions, he directly holds 18,876 shares of common stock. The exercise and subsequent sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025.
United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at a conversion price of $146.03 per share and sold the resulting 9,500 shares in multiple open‑market trades on March 23, 2026.
The sales occurred at weighted average prices ranging from about $517.81 to $536.55, pursuant to a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. After these transactions, she holds 40,513 shares directly, plus indirect holdings including 166 shares held by her spouse and family trust positions of 324,518, 258,117, 45,596 and 10,962 shares.
UNITED THERAPEUTICS Corp director Judy D. Olian reported an open-market sale of 200 shares of common stock at $530 per share. The transaction occurred on March 23, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan entered into on November 4, 2025. After this sale, she directly holds 4,245 shares of UNITED THERAPEUTICS common stock.
United Therapeutics Chairperson and CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share. She then sold 9,500 shares of common stock in a series of open-market transactions at prices above $520 per share, creating an exercise-and-sell pattern.
The filing shows she holds 40,513 common shares directly after these trades, plus indirect holdings including 166 shares held by her spouse and trust holdings of 324,518, 258,117, 45,596 and 10,962 shares. The exercise and resulting sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which may continue until up to 1,734,410 stock options expiring on March 17, 2027 are exercised or until December 31, 2026.
Judy Olian reports a proposed sale of 200 shares of Common Stock of UTHR via Form 144. The filing lists the securities as Restricted Stock acquired 06/26/2021. The filing also records three prior sales of 200 shares each on 03/02/2026, 03/09/2026, and 03/16/2026 with proceeds shown as 101,910.00, 102,000.00, and 107,088.00, respectively.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and then sold the same 9,500 shares in multiple open-market transactions.
The sales occurred on March 19, 2026 at weighted-average prices ranging from about $524.62 to $532.90, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 40,513 shares directly and also reports indirect holdings through her spouse and family trusts, including 324,518 shares held by a family trust.
United Therapeutics Corp Chairperson & CEO Martine Rothblatt reported a pre-planned options exercise and sale. She exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and received 9,500 shares of common stock.
On the same date, she sold 9,500 shares of common stock in multiple open-market transactions at prices generally between the $522 and $540 range, under a Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 40,513 shares directly, plus additional indirect holdings through her spouse and several family trusts.